Provided by Tiger Trade Technology Pte. Ltd.

Black Diamond Therapeutics, Inc.

2.14
+0.10004.90%
Post-market: 2.150.0101+0.47%19:30 EDT
Volume:561.28K
Turnover:1.18M
Market Cap:122.60M
PE:-2.87
High:2.16
Open:2.08
Low:2.05
Close:2.04
52wk High:4.94
52wk Low:1.60
Shares:57.29M
Float Shares:52.60M
Volume Ratio:1.02
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7446
EPS(LYR):0.3900
ROE:-37.21%
ROA:-19.11%
PB:1.28
PE(LYR):5.49

Loading ...

Black Diamond Therapeutics to Join H.C. Wainwright Global Investment Conference Fireside Chat

Reuters
·
3 hours ago

Scholar Rock Q2 Net Loss Narrows

Reuters
·
Aug 06

Black Diamond Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)

TIPRANKS
·
Aug 06

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

Reuters
·
Aug 06

Black Diamond Therapeutics Q2 Basic EPS USD -0.17

THOMSON REUTERS
·
Aug 06

Black Diamond Therapeutics Q2 Income from Operations USD -12.057 Million

THOMSON REUTERS
·
Aug 06

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 06

Black Diamond Therapeutics Inc Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Black Diamond Shareholders Approve Directors and Annual Say-on-Pay

TIPRANKS
·
Jun 30

Black Diamond Therapeutics Holds Annual Stockholder Meeting Via Webcast

Reuters
·
Jun 30

Wedbush Remains a Buy on Black Diamond Therapeutics (BDTX)

TIPRANKS
·
Jun 01

Black Diamond Therapeutics CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 22

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
May 22

Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC

Reuters
·
May 22

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline Nsclc Patients With Egfr Non-Classical Mutations

THOMSON REUTERS
·
May 22

Black Diamond Therapeutics Inc - 150 Mg Once Daily Dose Supported for Pivotal Development

THOMSON REUTERS
·
May 22

Black Diamond Therapeutics Inc - Preliminary Median Pfs 15.2 Months; Median Duration of Response Not Reached

THOMSON REUTERS
·
May 22

Black Diamond Therapeutics Inc - No New Safety Signals Observed; Adverse Event Profile Manageable

THOMSON REUTERS
·
May 22

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

GlobeNewswire
·
May 19